| Somatic RHOA mutation in angioimmunoblastic T cell lymphoma M Sakata-Yanagimoto, T Enami, K Yoshida, Y Shiraishi, R Ishii, Y Miyake, ... Nature genetics 46 (2), 171-175, 2014 | 693 | 2014 |
| Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study … M Yamaguchi, YL Kwong, WS Kim, Y Maeda, C Hashimoto, C Suh, ... J Clin Oncol 29 (33), 4410-4416, 2011 | 667 | 2011 |
| Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers K Kataoka, Y Shiraishi, Y Takeda, S Sakata, M Matsumoto, S Nagano, ... Nature 534 (7607), 402-406, 2016 | 651 | 2016 |
| Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ... New England Journal of Medicine 386 (4), 351-363, 2022 | 397 | 2022 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed … M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ... The Lancet 399 (10343), 2294-2308, 2022 | 373 | 2022 |
| AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma JP Leonard, M Trneny, K Izutsu, NH Fowler, X Hong, J Zhu, H Zhang, ... Journal of clinical oncology 37 (14), 1188, 2019 | 370 | 2019 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 308 | 2021 |
| Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory … M Yamaguchi, R Suzuki, YL Kwong, WS Kim, Y Hasegawa, K Izutsu, ... Cancer science 99 (5), 1016-1020, 2008 | 296 | 2008 |
| The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling K Izutsu, M Kurokawa, Y Imai, K Maki, K Mitani, H Hirai Blood, The Journal of the American Society of Hematology 97 (9), 2815-2822, 2001 | 291 | 2001 |
| Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type R Suzuki, M Yamaguchi, K Izutsu, G Yamamoto, K Takada, Y Harabuchi, ... Blood, The Journal of the American Society of Hematology 118 (23), 6018-6022, 2011 | 214 | 2011 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 202 | 2019 |
| Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis Y Imai, M Kurokawa, K Izutsu, A Hangaishi, K Takeuchi, K Maki, S Ogawa, ... Blood, The Journal of the American Society of Hematology 96 (9), 3154-3160, 2000 | 202 | 2000 |
| Gain‐of‐function mutations and copy number increases of Notch2 in diffuse large B‐cell lymphoma S Lee, K Kumano, K Nakazaki, M Sanada, A Matsumoto, G Yamamoto, ... Cancer science 100 (5), 920-926, 2009 | 185 | 2009 |
| ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma GS Nowakowski, A Chiappella, RD Gascoyne, DW Scott, Q Zhang, ... Journal of Clinical Oncology 39 (12), 1317-1328, 2021 | 184 | 2021 |
| Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese … D Ennishi, Y Maeda, N Niitsu, M Kojima, K Izutsu, J Takizawa, ... Blood, The Journal of the American Society of Hematology 116 (24), 5119-5125, 2010 | 166 | 2010 |
| The evi‐1 oncoprotein inhibits c‐Jun N‐terminal kinase and prevents stress‐induced cell death M Kurokawa, K Mitani, T Yamagata, T Takahashi, K Izutsu, S Ogawa, ... The EMBO journal, 2000 | 153 | 2000 |
| FDG-PET in T-cell and NK-cell neoplasms S Kako, K Izutsu, Y Ota, Y Minatani, M Sugaya, T Momose, K Ohtomo, ... Annals of oncology 18 (10), 1685-1690, 2007 | 150 | 2007 |
| Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm T Aoki, R Suzuki, Y Kuwatsuka, S Kako, K Fujimoto, J Taguchi, T Kondo, ... Blood, The Journal of the American Society of Hematology 125 (23), 3559-3562, 2015 | 147 | 2015 |
| Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma A Masuda, K Nakamura, K Izutsu, K Igarashi, R Ohkawa, M Jona, ... British journal of haematology 143 (1), 60-70, 2008 | 139 | 2008 |
| AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues Y Yamaguchi, M Kurokawa, Y Imai, K Izutsu, T Asai, M Ichikawa, ... Journal of Biological Chemistry 279 (15), 15630-15638, 2004 | 127 | 2004 |
